139 related articles for article (PubMed ID: 25034098)
1. Discovery of small-molecule Ras inhibitors that display antitumor activity by interfering with Ras·GTP-effector interaction.
Shima F; Yoshikawa Y; Matsumoto S; Kataoka T
Enzymes; 2013; 34 Pt. B():1-23. PubMed ID: 25034098
[TBL] [Abstract][Full Text] [Related]
2. In silico discovery of small-molecule Ras inhibitors that display antitumor activity by blocking the Ras-effector interaction.
Shima F; Yoshikawa Y; Ye M; Araki M; Matsumoto S; Liao J; Hu L; Sugimoto T; Ijiri Y; Takeda A; Nishiyama Y; Sato C; Muraoka S; Tamura A; Osoda T; Tsuda K; Miyakawa T; Fukunishi H; Shimada J; Kumasaka T; Yamamoto M; Kataoka T
Proc Natl Acad Sci U S A; 2013 May; 110(20):8182-7. PubMed ID: 23630290
[TBL] [Abstract][Full Text] [Related]
3. Molecular Basis for Allosteric Inhibition of GTP-Bound H-Ras Protein by a Small-Molecule Compound Carrying a Naphthalene Ring.
Matsumoto S; Hiraga T; Hayashi Y; Yoshikawa Y; Tsuda C; Araki M; Neya M; Shima F; Kataoka T
Biochemistry; 2018 Sep; 57(36):5350-5358. PubMed ID: 30141910
[TBL] [Abstract][Full Text] [Related]
4. Current status of the development of Ras inhibitors.
Shima F; Matsumoto S; Yoshikawa Y; Kawamura T; Isa M; Kataoka T
J Biochem; 2015 Aug; 158(2):91-9. PubMed ID: 26100833
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological modulation of oncogenic Ras by natural products and their derivatives: Renewed hope in the discovery of novel anti-Ras drugs.
Quah SY; Tan MS; Teh YH; Stanslas J
Pharmacol Ther; 2016 Jun; 162():35-57. PubMed ID: 27016467
[TBL] [Abstract][Full Text] [Related]
6. A distinct class of dominant negative Ras mutants: cytosolic GTP-bound Ras effector domain mutants that inhibit Ras signaling and transformation and enhance cell adhesion.
Fiordalisi JJ; Holly SP; Johnson RL; Parise LV; Cox AD
J Biol Chem; 2002 Mar; 277(13):10813-23. PubMed ID: 11799108
[TBL] [Abstract][Full Text] [Related]
7. Slow conformational dynamics of the guanine nucleotide-binding protein Ras complexed with the GTP analogue GTPgammaS.
Spoerner M; Nuehs A; Herrmann C; Steiner G; Kalbitzer HR
FEBS J; 2007 Mar; 274(6):1419-33. PubMed ID: 17302736
[TBL] [Abstract][Full Text] [Related]
8. State 1(T) inhibitors of activated Ras.
Kalbitzer HR; Spoerner M
Enzymes; 2013; 33 Pt A():69-94. PubMed ID: 25033801
[TBL] [Abstract][Full Text] [Related]
9. Drugging the Undruggable: Advances on RAS Targeting in Cancer.
Molina-Arcas M; Samani A; Downward J
Genes (Basel); 2021 Jun; 12(6):. PubMed ID: 34200676
[TBL] [Abstract][Full Text] [Related]
10. A two-hybrid approach to identify inhibitors of the RAS-RAF interaction.
Khazak V; Eyrisch S; Kato J; Tamanoi F; Golemis EA
Enzymes; 2013; 33 Pt A():213-48. PubMed ID: 25033807
[TBL] [Abstract][Full Text] [Related]
11. In vitro evidence for the recognition of 8-oxoGTP by Ras, a small GTP-binding protein.
Yoon SH; Hyun JW; Choi J; Choi EY; Kim HJ; Lee SJ; Chung MH
Biochem Biophys Res Commun; 2005 Feb; 327(1):342-8. PubMed ID: 15629468
[TBL] [Abstract][Full Text] [Related]
12. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies.
Sebti SM; Hamilton AD
Oncogene; 2000 Dec; 19(56):6584-93. PubMed ID: 11426643
[TBL] [Abstract][Full Text] [Related]
13. DRoP: a water analysis program identifies Ras-GTP-specific pathway of communication between membrane-interacting regions and the active site.
Kearney BM; Johnson CW; Roberts DM; Swartz P; Mattos C
J Mol Biol; 2014 Feb; 426(3):611-29. PubMed ID: 24189050
[TBL] [Abstract][Full Text] [Related]
14. Flagellin and lipopolysaccharide stimulate the MEK-ERK signaling pathway in chicken heterophils through differential activation of the small GTPases, Ras and Rap1.
Kogut MH; Genovese KJ; He H
Mol Immunol; 2007 Mar; 44(7):1729-36. PubMed ID: 17045653
[TBL] [Abstract][Full Text] [Related]
15. Recent progress in developing small molecule inhibitors designed to interfere with ras membrane association: toward inhibiting K-Ras and N-Ras functions.
Tamanoi F; Lu J
Enzymes; 2013; 34 Pt. B():181-200. PubMed ID: 25034105
[TBL] [Abstract][Full Text] [Related]
16. Rit, a non-lipid-modified Ras-related protein, transforms NIH3T3 cells without activating the ERK, JNK, p38 MAPK or PI3K/Akt pathways.
Rusyn EV; Reynolds ER; Shao H; Grana TM; Chan TO; Andres DA; Cox AD
Oncogene; 2000 Sep; 19(41):4685-94. PubMed ID: 11032018
[TBL] [Abstract][Full Text] [Related]
17. What makes Ras an efficient molecular switch: a computational, biophysical, and structural study of Ras-GDP interactions with mutants of Raf.
Filchtinski D; Sharabi O; Rüppel A; Vetter IR; Herrmann C; Shifman JM
J Mol Biol; 2010 Jun; 399(3):422-35. PubMed ID: 20361980
[TBL] [Abstract][Full Text] [Related]
18. Discovery of Sulfonamide-Derived Agonists of SOS1-Mediated Nucleotide Exchange on RAS Using Fragment-Based Methods.
Sarkar D; Olejniczak ET; Phan J; Coker JA; Sai J; Arnold A; Beesetty Y; Waterson AG; Fesik SW
J Med Chem; 2020 Aug; 63(15):8325-8337. PubMed ID: 32673492
[TBL] [Abstract][Full Text] [Related]
19. COMBINE analysis of the specificity of binding of Ras proteins to their effectors.
Tomić S; Bertosa B; Wang T; Wade RC
Proteins; 2007 May; 67(2):435-47. PubMed ID: 17295314
[TBL] [Abstract][Full Text] [Related]
20. Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.
Friday BB; Adjei AA
Clin Cancer Res; 2008 Jan; 14(2):342-6. PubMed ID: 18223206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
